Abstract
Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost–effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using condition-specific data to generate QALYs. There are two main methods: mapping from the condition-specific data to a generic health-related quality of life measure; and direct valuation of condition-specific health states. Whether one believes condition-specific data are useful even if generic QALY data are available, or simply that condition-specific data are helpful in the absence of generic measures of health-related quality of life, it is timely to review recent research activity directed at making greater use of condition-specific data to inform assessments of cost–effectiveness.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.